Last update: June 30, 2015

Aliskiren

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

At latest update, relevant information on excretion into breast milk was not found.

Because of pharmacokinetic data (wide distribution volume and moderately high molecular weight) excretion into breast milk in significant quantity seems to be unlikely. Based on a low oral bioavailability, concentration in the infant's plasma should be nil or low, except in premature and newborn infants with a increased intestinal absorption capacity.

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Aliskiren in other languages or writings:

Tradenames

Main tradenames from several countries containing Aliskiren in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 2 - 3 %
Molecular weight 610 daltons
Protein Binding 47 - 51 %
VD 135 l/Kg
Tmax 1 - 3 hours
T1/2 34 - 41 hours

References

  1. EMEA. Aliskireno. Ficha técnica. 2012 Full text (in our servers)
  2. Belda-Rustarazo S, Vallejo-Rodríguez I, Molina-Carballo A, Cabeza Barrera J. Tratamiento de rescate con aliskiren en \ hipertensión maligna familiar en un \ lactante. \ [Salvage therapy with aliskiren in malignant familial hypertension in a breast-fed baby]. Farm Hosp. 2011 Abstract Full text (in our servers)
  3. Belda-Rustarazo S, Vallejo-Rodríguez I, Molina-Carballo A, Cabeza Barrera J. [Salvage therapy with aliskiren in malignant familial hypertension in a breast-fed baby]. Farm Hosp. 2011 Abstract
  4. Waldmeier F, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M, Valencia J, Riviere GJ, End P, Vaidyanathan S. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos. 2007 Abstract Full text (in our servers)
  5. Vaidyanathan S, Jermany J, Yeh C, Bizot MN, Camisasca R. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol. 2006 Abstract Full text (in our servers)

Total visits

2,105

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) from Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM